LAS VEGAS, July 16, 2026 /PRNewswire/ -- The treatment landscape for C3G has historically depended on the off-label use of multiple prescription therapies, underscoring the substantial unmet need for ...
Emerging therapies targeting novel mechanisms such as dual complement inhibitors (C5 and Factor H (KP104), MASP-3 inhibitors (Zaltenibart), RNA interference (RNAi) therapeutics targeting complement C3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results